Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BIOCORP : and DreaMed Diabetes Join to Offer an Outstanding AI System for Diabetes Treatment Compliance

share with twitter share with LinkedIn share with facebook
share via e-mail
02/21/2019 | 02:00am EDT

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, and DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that they are partnering concerning a global solution for diabetes compliance.

While exhibiting at ATTD – Advanced Technologies and Treatments for Diabetes - in Berlin, BIOCORP and DreaMed Diabetes present the content of their collaboration about diabetes compliance.

Since 2015, BIOCORP has been developing a smart cap for pen injectors newly renamed Mallya® (formerly known with the project name Easylog). The device is now taking an important step forward since attending an introduction to the market by end of H1-2019. For the record, Mallya® automatically captures data (dose, date and time) and sends the information in real time to a companion software thanks to Bluetooth technology, with a very high level of accuracy and repeatability.

For its part, DreaMed Diabetes has developed DreaMed AdvisorTM Pro, a cloud-based digital solution generating insulin delivery recommendations by analyzing information from CGM, self-monitoring blood glucose, and insulin pump data. Applying event-driven adaptive learning, Advisor Pro refines its understanding for each individual and sends recommendation to the healthcare provider on how to optimize a patient’s insulin pump settings for basal rate, carbohydrate ratio and correction factor. DreaMed intends to expand the capabilities of DreaMed Advisor to include decision support tools for healthcare professional treating persons with diabetes under basal or multiple daily injections therapy.

Mallya® is therefore completing the DreaMed Advisor concept by providing data related to insulin injections. Mallya® will be integrated to DreaMed Advisor for basal or multiple daily injections delivery by data collection, analysis and generating recommendation for the healthcare professional and person with diabetes. Mallya will be used in clinical trials of DreaMed during 2019.

This partnership is a real opportunity for our two companies and especially for final patients since it is a real progress concerning the management of diabetes treatment. This new step is significant for BIOCORP since 2019 is a major year for our connected devices: the launch to market of Mallya® is close and this partnership is one of the numerous milestones that will support our commercial success in the future “, declared Eric Dessertenne, COO of BIOCORP.

" For years, DreaMed Diabetes is dedicated to empowering people with diabetes and their care providers with innovative and person-centric digital treatment decision support technologies in order to improve health and quality of life", said Eran Agmon, DreaMed Diabetes Chief Product Officer. "This partnership will allow us to offer innovative decision support solutions for people with diabetes under basal only or multiple daily injections based on an accurate and reliable insulin dosing information."

Founded in 2004 in Issoire (near Clermont-Ferrand), France, BIOCORP is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, BIOCORP is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, BIOCORP continues to innovate in medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including Easylog, a smart cap for pen injectors that captures injection data and automatically transmits data to a mobile app, helping patients to manage their treatment. The company has a team of 45 employees. BIOCORP is listed on Alternext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
Follow us on Twitter @BIOCORPSystems

DreaMed spun out of Schneider Children’s Medical Center in 2014, following seven years developing its artificial pancreas technology. Since then, DreaMed Diabetes develops solutions and personalized decision support solutions for the optimization of insulin therapy for people with Type 1 and Type 2 diabetes. The Company’s first product, GlucoSitter, was developed for closed-loop insulin therapy and was licensed to Medtronic Diabetes. The Company then developed Advisor, a portfolio of decision support solutions for patients and healthcare providers dedicated to transform dynamic, real-world patient data into actionable treatment insights with its unique, cloud-based cognitive technology. Investors in the Company include Medtronic Diabetes, Norma Investments and OurCrowd. For more information, please visit https://ww.dreamed-diabetes.com

© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOCORP
06/30BIOCORP : Signs Distribution Agreement for Mallya Technology With Roche Diabetes..
06/22BIOCORP : Announces Initiation of Coverage by Gilbert Dupont
06/19BIOCORP : and Théa Sign a Partnership for the Development of Innovative Digital ..
04/09BIOCORP : 2019 annual results
04/09BIOCORP : 2019 Annual Results
04/09BIOCORP : Annual results
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
02/12BIOCORP : Strong Revenue Growth In 2019
More news
Sales 2020 15,3 M 17,4 M 17,4 M
Net income 2020 0,60 M 0,68 M 0,68 M
Net cash 2020 1,17 M 1,33 M 1,33 M
P/E ratio 2020 187x
Yield 2020 0,05%
Capitalization 116 M 132 M 132 M
EV / Sales 2019
EV / Sales 2020 7,53x
Nbr of Employees 52
Free-Float 51,3%
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 31,35 €
Last Close Price 28,10 €
Spread / Highest target 13,9%
Spread / Average Target 11,6%
Spread / Lowest Target 9,25%
EPS Revisions
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.41%389 709
ROCHE HOLDING AG5.59%300 114
MERCK & CO., INC.-13.96%197 511
PFIZER, INC.-10.08%195 697
NOVARTIS AG-11.32%191 193